Reply DR

 Reply DR Pacemaker

 

...it's all the heart asks for...

 

Good things come in small packages. However, when an 8cc pacemaker delivering proven therapies such as SafeR™ comes along, suddenly "Good" and "Small" just don’t cut it.

 

99.9%4 intrinsic conduction

 

  • CLINICALLY PROVEN

    99.9% intrinsic conduction4

  • SMART PATIENT FOLLOW-UP

    Automatic All the Way

  • 8cc, 9 YEARS5

    No pacemaker this small lasts longer

 

The MOST Study Results:

Unnecessary ventricular pacing increases the risk of atrial fibrillation and heart failure hospitalization1.

 

SaveR Clinical Results:

SafeR ensures 99.9% intrinsic conduction4.

 

Prevention of Ventricular Pacing:AV Hysteresis vs. SafeR

 

  • SafeR has significantly reduced ventricular pacing to a mean of 0.5% and a median of less than 0.1% (n=183)2

  • 90% of sinus node disease (SND) and 70% of paroxysmal AVB patients had less than 0.5% pacing (n=117)3

 

“I’ve been using the first generation of SafeR™ since its introduction in 2003. This exclusive pacing technology has brought tremendous benefits to my patients who are now given chances to rely on their heart’s natural conduction when it is intact. It has become the gold-standard for a vast majority of my dual-chamber pacemaker patients”

Professor Johannes Brachman, Klinikum Coburg, Germany

 

Technical Specs

  • Pacing Mode: SafeR inside

  • Size: 8 cc

  • Longevity: 9 years

  • AF Prevention Algorithms: Overdriving, Pause Supression, PAC Acceleration

  • Rate Response: Dual Sensor (Minute Ventilation, Accelerometer)

  • EGM: 5 min, A and V

  • Diagnosis: Automatic Data Analysis with Programming Advice

 

Safer

Automatic All the Way

 

It as easy as: 1,2,3...

1. Interrogate and get COMPLETE data analysis

2. Run ALL sensing and pacing thresholds

3. End session, print summary and save FULL report

 

 

Click here for a better view

 

 

Intended uses, indications, contraindications


 

 


1. Sweeney M et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial to pacemaker therapy for sinus node dysfunction. Circulation 2003; 107:2932-2937.
2. Davy JM et al. Determining the optimal pacing mode to prevent ventricular pacing: SAVE R study results. Heart Rhythm 2006; 3, supp 5, S169, P2-94 (abs).
3. Defaye P et al. Impact of pacing indication on AAIsafeR2: efficacy to suppress ventricular pacing, Europace 2006; 8 supp 1, 223-4 (abs).
4. "99.9% intrinsic AV conduction in 28/35 (80%) of patients of non-selected DDD patients" Anselme et al. First clinical results of AAIsafeR2, a new mode to prevent ventricular pacing. Heart Rhythm 2005; 2, supp 5; p4-99 (abs).
5. 100% A pacing, safeR-R, 70 min-1, 2.5 V, 0.5 ms, 500 Ω, Diagnostics ON.



Documentation

Brochure

Technical Specifications